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Abstract
Objectives To evaluate the risk of venous thromboembolic events
associated with the use of progestin-only contraception and whether
that risk differs with the mode of drug delivery (oral, intrauterine, or depot
injection).
Design Systematic review and meta-analysis of randomised controlled
trials and observational studies.
Data sources Pubmed, Embase, Cochrane Library, and reference lists
of relevant reviews.
Study selection Randomised controlled trials and case-control, cohort,
and cross sectional studies with venous thromboembolic outcome for
progestin-only contraception reported relative to a non-hormone
comparator group.
Data extraction Data were extracted by two independent investigators,
and consensus for inclusion was reached after assessment by additional
investigators.
Results Among the 2022 unique references identified by all searches,
eight observational studies fulfilled inclusion criteria. A total of 147 women
across all studies were diagnosed with a venous thromboembolic event
while taking progestin-only contraception, and the summary measure
for the adjusted relative risk of a venous thromboembolic episode for
users versus non-users of a progestin-only contraceptive was, based
on the random effects model, 1.03 (95% CI 0.76 to 1.39). Subgroup
analysis confirmed there was no association between venous
thromboembolic risk and progestin-only pills (relative risk 0.90 (0.57 to
1.45)) or a progestin intrauterine device (0.61 (0.24 to 1.53)). The relative
risk of a venous thromboembolic event for users of an injectable progestin
versus non-users was 2.67 (1.29 to 5.53).
Conclusions Published data assessing the risk of venous
thromboembolism in women prescribed progestin-only contraception
are limited. In this meta-analysis of eight observational studies, the use
of progestin-only contraception was not associated with an increased
risk of venous thromboembolism compared with non-users of hormonal
contraception. The potential association between injectable progestins
and thrombosis requires further study.
Introduction
Since their introduction in the 1960s, combined
oestrogen-progestin oral contraceptives have been associated
with an increased risk of venous thromboembolic events. This
thrombotic risk was attributed to the oestrogen content, which
prompted the development of oral contraceptives containing
less oestrogen. Use of formulations containing lower dose
oestrogen still confer about twofold to fourfold increased risk
of venous thromboembolic events compared with non-use.
1-5
Epidemiological data suggest that subsequent changes in the
composition of combined oral contraceptives by altering the
progestin content can exacerbate thrombotic risk. Accordingly,
newer progestins such as desogestrel, gestodene, and
norgestimate have been associated with a greater venous
thromboembolic risk than the older progestins such as
levonorgestrel, lynestrenol, and norethisterone.
4-8 When
combined with an oestrogen, the newer progestins increase
activatedproteinCresistancemorethanolderprogestins,which
may account for the observed increased incidence of venous
thromboembolism.
9-12 Despite evidence that progestins may
influence the risk of venous thromboembolism, there are only
limited data evaluating the association between progestin-only
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Research
RESEARCHcontraception and thrombosis. Progestin-only contraception is
generally thought to pose little risk of thrombosis and is
recommended for women at high risk—such as post partum or
with hereditary thrombophilia or a history of venous
thromboembolism.
13 14Weperformedameta-analysistoevaluate
the risk of venous thromboembolism associated with
progestin-only contraception.
Methods
Weperformedasystematicreviewandmeta-analysisofstudies
to evaluate the hypothesis that progestin-only contraceptives
do not increase the risk of venous thromboembolic events. We
conducted a literature search of journal articles published on or
before 31 December 2011 using PubMed, Embase, and the
Cochrane Database of Systematic Reviews. The index (MeSH
or Emtree) fields were queried for the key words “progestin,”
“progesterone,” “progestogen,” “progestagen,” “gestagen,”
“contraceptive,” “thrombosis,” “thromboembolism,” and
“thrombotic” (see appendix on bmj.com). Because of available
resources, we considered only English language publications.
We also performed a hand search of all the references included
in a previous meta-analysis that analysed progesterone-only
contraception and the risk of venous thromboembolic events
15
and a review of contraception in thrombophilic adolescents.
16
Inclusion criteria
Studieswereincludediftheymetallofthefollowingconditions:
a randomised trial or case-control, cohort, or cross sectional
study (prospective or retrospective); presence of a treatment
armfeaturinguseofprogestin-onlycontraceptivesandacontrol
arm with no hormone use; use of progestin for the purpose of
contraception only (excluding postcoital contraception);
independent analysis of premenopausal women; incidence of
venous thromboembolic events (defined as deep venous
thrombosis or pulmonary embolism) reported; study featured
human data only; one or more of three possible administration
routes (oral, injectable, or intrauterine) were considered.
Data extraction
The initial search of the three databases was performed by SM;
the references obtained were screened independently by two
reviewers(RKandVR).Abstractswereassessedforrelevance,
and the full text of potentially suitable articles were retrieved.
Each of those papers was assessed independently by the two
reviewers (RK and VR) for inclusion in the meta-analysis; the
reason for exclusion was noted for rejected articles. Two other
reviewers(SMandJIZ)readthefinalsubsetofpapersretained;
mutual consensus was required for a study to be included in the
analysis.
Validity assessment
Two reviewers (SM and JIZ) independently qualitatively
evaluated the risk of confounding and the design quality of
selected studies. Observational studies were assessed as
suggested by the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) Group.
17 The characteristics of
individuals in the case and control groups or exposed and
unexposed patients were compared; the use of matching or
stratification was noted, and covariates used for adjustment in
multivariate analysis were recorded. For randomised trials, the
plan was to use the Cochrane Collaboration’s tool for assessing
risk of bias.
18
Statistical analysis
We estimated the risk ratio of venous thromboembolism for
users of progestin-only oral contraceptives versus non-users.
Venous thromboembolism was defined as including both deep
venousthrombosisandpulmonaryembolism.Weassumedthat
venous thromboembolic events had a low incidence (<10% a
year) in women aged <50 years taking oral contraceptives; this
was based on previous reports estimating the yearly incidence
of those events to about 0.06% per year.
4 For infrequent events,
theriskratio,oddsratio,andrateratioareconsideredequivalent
measures of relative risk.
19 With this in mind, we used the
Comprehensive Meta-Analysis (CMA) version 2.2 software
platform,enteringeachmeasureofrelativeriskinthesamedata
table as if it were a risk ratio. The DerSimonian and Laird
random effects model was used with the study as the unit of
analysis.Theprimaryanalysiswasperformedwiththeadjusted
measures of effect.
As a secondary analysis, we estimated the adjusted risk ratio of
venous thromboembolism for users versus non-users of a
hormone in each subgroup according to route of administration
(oral, injectable and intrauterine). Additionally, an unadjusted
odds ratio of venous thromboembolic event for users versus
non-users of progestin was calculated using the raw event data.
Heterogeneity across studies was estimated by means of the I
2
statistic,itselfcalculatedfromtheQstatistic.Sensitivityanalysis
was performed by repeating the primary analysis while
excluding selected subgroups in order to determine if they had
an inordinate effect on the estimated measure of effect.
Results
A total of 2045 references were identified: 1827 from PubMed,
215 from Embase, and none from the Cochrane Database of
Systematic Reviews (fig 1⇓). Two journal articles were
identified from reading reviews of the subject matter,
15 16 20 21
and one from personal knowledge of an author.
22 After removal
of duplicates, 2022 records remained and were screened for
inclusion in the analysis. Of these, 1922 were excluded after
reviewoftheabstractforlackofpertinence,leaving100articles
to be retrieved. The full text of these papers were evaluated: 92
were excluded, with eight remaining for analysis.
20 22-28 The
reasons for exclusion were not being a case-control or cohort
studyorrandomisedtrial(n=41),resultsnotreportedseparately
for a progestin-only arm (n=39), absence of a no hormone arm
(n=4), progestin not administered for contraception only (n=4),
results for venous thromboembolism not reported (n=3), and
old version of a study with a recent update (n=1).
Characteristics of included studies
The methods used by the authors of the eight selected studies
are summarised in table 1⇓. Our search found no randomised
trial including a group of women taking a progestin-only
contraceptive versus a group taking no hormone; three studies
were retrospective cohort analyses, and five were case-control
studies. All the case-control studies matched participants by
age, and all but one study evaluated patients taking a
progesterone-only pill with some also including individuals
with a depot or intrauterine progestin-only contraceptive. Only
twostudiesmadeuseofstratification,butallofthemperformed
multivariateanalysis.Theregressiontechniquesvariedwidely:
logistic regression was the most common approach,
20 26-28
followedbyPoissonregression
23 24andCoxmodelling.
22 23Body
mass index was the variable most commonly adjusted for, with
five sets of authors using it in their model. Two of the three
retrospective cohort studies adjusted results for age in
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RESEARCHmultivariate analysis. After considering these details, our
reviewers determined that all of the eight papers retrieved in
the search were of sufficient quality to be included in the
meta-analysis.
Atotalof147womensustainedavenousthromboembolicevent,
and table 2⇓ shows the results of the articles retained for final
analysis. The largest study was that of Lidegaard et al,
24 with
1882 episodes of venous thromboembolism recorded in the
combined group of individuals exposed to a progestin or to no
hormone, followed by the WHO study,
27 which featured 667
casesofvenousthromboembolismforprogestin-onlyusersand
non-users. The remaining six papers included a total of 777
events. The mean ages of case and control groups or exposed
and unexposed groups were similar in the articles where the
data were available. Since logistic regression was used in most
papers, the odds ratio was the most common measure of effect.
Risk of venous thromboembolism
The adjusted relative risk of a venous thromboembolic event
forusersofprogestin-onlycontraceptionversusnon-usersvaried
from 0.68 to 1.93, as shown in table 3⇓. None of the studies
reportedastatisticallysignificantdifferenceintheriskofvenous
thromboembolic event for users versus non-users of
progestin-only contraceptive, whether for subgroups of users
orallusersversusnon-users.However,Lidegaardetalreported
the results for three different progestin-only formulations
separately.
24 We combined these three risk ratio estimates,
corresponding to the three progestins, using the random effect
modelsandsettingthestudyastheunitofanalysis.Weassumed
the three estimates were independent because there was
insufficientinformationtoaccountfortheirdependence.Hence
the confidence interval of the estimate (0.61 to 0.98) may be
too narrow (table 2⇓).
The summary measure for the adjusted relative risk of a venous
thromboembolic event for users versus non-users of a
progestin-only contraceptive was 1.03 (95% CI 0.76 to1.39)
with the random effects model (fig 2⇓). This value was similar
totheoneobtainedbycombiningthecruderesults(relativerisk
1.21 (0.92 to 1.59)). However, the largest study (by Lidegaard
et al
24) could not be included in this latter estimate because the
numbers of exposed and unexposed individuals were not
provided (fig 3⇓).
Subset analysis was performed on the adjusted results with the
randomeffectsmodel.Atotalof54womendevelopedavenous
thromboembolic event while taking a progestin-only pill
(excluding the study by Vasilakis et al,
25 which did not specify
the route of administration), and they showed no significant
increase in risk of venous thromboembolism compared with
non-users (relative risk 0.90 (0.57 to 1.45)). On the other hand,
the relative risk of an event for users of an injectable progestin
formulation versus non-users was 2.67((1.29 to 5.53) (fig 4⇓).
Only two studies could be used to compute this value because
nootherarticlereportedtheresultsseparatelyforthatsubgroup.
Thosetwopapersfeaturedatotalof31venousthromboembolic
events in users of injectable progestins, which represents 21%
ofallcasesinprogestin-onlyusersamongalloftheeightstudies.
Similarly, only two papers reported the results for the risk of
venous thromboembolism in users of a progestin-only
intrauterine device, and the combined measure of effect was
0.61 (0.24 to 1.53). These two studies reported 58
thromboemboliceventsinusersofaprogestin-onlyintrauterine
device, which corresponds to 39% of all such episodes in
progestin-only users among all of the eight studies. Notably,
mostoftheinformationonthesethromboemboliceventscomes
from Lidegaard et al,
24 with 55 venous thromboembolic event
episodes in comparison with only three episodes in the paper
from van Hylckama Vlieg et al.
26
Heterogeneity was low, with an I
2 of 24% and P=0.24 for the
adjusted results (fig 2⇓). Sensitivity analysis was done by
repeating the meta-analysis with one of the studies removed on
aniterativebasis:foralliterations,the95%confidenceintervals
overlapped largely with those of the main analysis (data not
shown).
Discussion
The primary objective of this meta-analysis is to assess the risk
of venous thromboembolic events in women taking
progestin-only contraception compared with non-users. A total
ofeightstudieswereincludedinthisanalysis,andthesummary
statistic did not identify a significant risk of venous
thromboembolism associated with use of progestin-only
contraception.Therewasalowdegreeofheterogeneitybetween
studies, and we performed subgroup analysis to determine
whether the apparent lack of association with venous
thromboembolism was independent of route of administration
of progestin (oral, depot injection, or intrauterine device).
All studies except that of van Hylckama Vlieg et al
26 included
patients taking an oral progestin; pooling of the results for the
five papers reporting results separately for that subgroup
indicated no increase in risk of venous thromboembolism for
users versus non-users. The oral formulations included in this
meta-analysis consisted of numerous different compounds, so
it is not possible to evaluate a relation between risk of venous
thromboembolism and individual types of progestin. In the
studiesthatincludedwomenusingaprogestin-onlyintrauterine
device,noexcessriskofvenousthromboembolismwasdetected.
However, our analysis suggests that depot administration more
than doubles the risk of venous thromboembolism. Only two
studiesreportedresultsseparatelyforthissubgroup,representing
about a fifth of the total number of venous thromboembolic
episodes in the progestin-only users for the eight studies.
The relative safety of progestin-only contraception by oral and
intrauterine delivery may in part be explained by dose,
absorption, or metabolism. The amount of progestin included
in a progestin-only “mini-pill” is considerably less than that
commonly supplied in a combined oestrogen-progestin oral
contraceptive.Forinstance,norethindroneistheonlymarketed
progestin-only pill marketed in the United States, and when
used alone the dose is 0.35 mg daily or about a third of the dose
commonly found in combined oestrogen-progestin
formulations.
29 Similarly, the levonorgestrel-containing
intrauterinedevicereleasesabout20μgoflevonorgestreldaily,
most of which is concentrated in the endometrium with plasma
concentrations ranging between 74 and 166 pg/mL.
30 By
comparison, after intramuscular injection of
medroxyprogesterone 150 mg, the peak plasma concentration
is 2500–7000 pg/mL and remains greater than 430 pg/mL at
three months.
31 32
Different progestins are also known to influence the risk of
thrombosis differently. Evidence suggests that third generation
progestins such as desogestrel in combination with oestrogen
are more prothrombotic than earlier formulations such as
levonorgestrel or norethisterone.
4-8 24 Progestins can modulate
oestrogeninducedactivatedproteinCresistance
12andhavebeen
shown to influence the cellular expression of tissue factor
33 34
as well as circulating tissue factor pathway inhibitor.
10 35 In a
mouse model of vascular injury administration of
medroxyprogesterone significantly shortened the time to
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RESEARCHdevelopmentofanocclusivethrombus.
36Inthestudiesincluded
in this meta-analysis, the vast majority of women used older
progestins, potentially masking an association with venous
thromboembolism. However, the study by Lidegaard et al
analysed more than 29 000 women years for a third generation
progestin-only pill and failed to show any increased risk
associated with its use (adjusted venous thromboembolic event
rate 0.64 (95% confidence interval 0.29 to 1.42)).
24
Strengths and limitations of the meta-analysis
A potential limitation of this study remains the paucity of
publishedliteratureonthetopic,withatotalofonlyeightstudies
available for analysis and no randomised trials. The inclusion
of several recently published large epidemiological studies
permitsamorerobustsummaryanalysiswithtighterconfidence
intervals than a previously published meta-analysis, which
evaluated only four studies (without an analysis according to
methodofdelivery).
15Theconsistencyoftheresultsfordifferent
oral formulations reassures the validity of the measure of effect
for this group. The subgroup analysis for intrauterine devices
anddepotinjectionsshouldbeinterpretedwithcautionbecause
of the limited number of studies available for analysis.
Control for confounding in the individual studies was usually
limited. Also, selection bias cannot be excluded as the basis of
the significant association between depot administration and
venousthromboembolism.However,thisisunlikelyasthestudy
thatcontributedmosttothesummarystatisticfordepotinjection
specifically excluded highest risk women (that is, those with a
personal history of venous thromboembolism).
26 We did not
observeevidenceofpublicationorreportingbias.However,the
small number of studies limits our ability to formally assess
these potential biases.
37 Bias and lack of adjustment for
confounders at the level of the individual studies cannot be
corrected in the meta-analysis, so the validity of these results
is dependent on quality of the primary observational data.
Implications for patient care
Deciding on the optimal contraceptive method is often difficult
for women considered at increased risk of venous
thromboembolism,suchasthosewithahistoryofthrombophilia.
The World Health Organization and US Centers for Disease
Control and Prevention publish similarly titled guidelines on
the topic, “Medical eligibility criteria for contraceptive use.”
All modes of progestin-only contraception are advocated, even
for higher risk women such as those with hereditary
thrombophilia, history of oestrogen induced venous
thromboembolism, or history of recurrent venous
thromboembolism.
13 14 This meta-analysis offers further
reassurance that such guidance is appropriate. However, only
two of the studies were specifically conducted in high risk
populations, with a total of 360 women.
22 23 Our analysis also
suggests that the relative safety of progestin-only agents may
be limited to oral and intrauterine formulations, whereas the
thrombotic risk associated with injectable progestin seems to
be of similar magnitude to oral contraceptives containing
oestrogen.
Conclusion
Collectively,progestin-onlycontraceptiveswerenotassociated
with an increased risk of venous thromboembolism compared
with non-users in a limited number of observational studies. In
the subset of women in this analysis prescribed injectable
progestins, there was an approximate twofold increase in
thrombotic risk. These results require confirmation as selection
biascannotbeexcluded.Intheinterim,wesuggestconsideration
of non-injectable forms of progestin-only contraception for
highest risk women.
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RESEARCHTables
Table 1| Characteristics of studies included in review of risk of venous thromboembolic events in women taking progestin-only contraceptives
Adjustment factors in
multivariate analysis Stratification† Matching Format Baseline risk* Inclusion criteria Study
BMI, recent hospitalisation,
recent surgery, nursing home
confinement, trauma or fracture,
active cancer, leg paresis,
varicose veins
No Age and
medical record
number
Case-control Average Cases: diagnosis of deep vein
thrombosis or pulmonary embolism
Barsoum et al, 2010
28
BMI, age, thrombophilia No No Retrospective
cohort
High Personal history of VTE with
presence of thrombophilia or family
history of VTE
Conard et al, 2004
23
BMI, hypertension, smoking,
diabetes, alcohol consumption,
education
No Age Case control Average Cases: diagnosis of myocardial,
thromboembolic cerebrovascular
accident or VTE
Heinemann et al,
1999
20
Age, calendar year, level of
education
Certainty of
diagnosis
No Retrospective
cohort
Average All Danish women aged 15-49
years in 1995-2009
Lidegaard et al,
2011
24
Duration of exposure No No Retrospective
cohort
High One episode of VTE during use of
combined oral contraceptive or <1
month after stopping
Vaillant-Roussel et
al, 2011
22
BMI, smoking No Age and
general
practice
Case-control Average Cases and controls: to have
received ≥1 prescription for a
progestin alone. Cases: idiopathic
VTE
Vasilakis et al, 1999
25
Age No Age Case-control Average Cases: first episode of VTE Van Hylckama Vlieg
et al, 2010
26
BMI, number of live births,
hypertension, rheumatic heart
disease, family history of
premature heart attack
Europe v
developing
countries, history
of hypertension,
smoking status
Age Case-control Average Cases: VTE, stroke, or acute
myocardial infarction
WHO, 1998
27
VTE=venous thromboembolic event. BMI=body mass index.
*Subjective assessment based on inclusion criteria.
†Within the group of cancer-free women receiving a progestin-only agent.
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RESEARCHTable 2| Progestin exposure characteristics in studies of venous thromboembolic events in women taking progestin-only contraceptives
Duration of exposure Progestin used No of patients
Study
Controls or
unexposed*
Cases or
exposed* Dose Drug Route
Without
VTE* With a VTE*
N/A 5 or 10 mg/day Medroxyprogesterone
acetate†
Oral 1 1 Barsoum et al,
2010
28
150 or 400 mg Medroxyprogesterone
acetate†
Inject 1 2
Mean 35.0 (SD
17.7) months
Mean 31.2 (SD
19.7) months
10 mg daily, 18-20
days/cycle
Chlormadinone acetate Oral 99 3 Conard et al,
2004
23
N/A N/A Oral 54 7 Heinemann et al,
1999
20
44168 women years N/A Norethisterone Oral N/A 9 Lidegaard et al,
2011
24
29187 women years Desogestrel 6
155149 women years Levonorgestrel IUD 55
Median 74 (range 3-434) months N/A Oral 27 7 Vaillant-Roussel
et al, 2011
22
N/A N/A Oral 26 2 Vasilakis et al,
1999
25
Inject
N/A N/A Medroxyprogesterone Inject 15 20 Van Hylckama
Vlieg et al,
2010
26 Levonorgestrel IUD 26 3
N/A 0.03 mg Levonorgestrel Oral 63 21 WHO, 1998
27
0.075 mg Norgestrel
0.5 mg Ethynodiol diacetate
0.5 mg Lynestrenol
0.35 mg Norethisterone
150 mg Medroxyprogesterone IUD 34 11
200 mg Norethisterone oenanthate
VTE=venous thromboembolic event. N/A=data not available from the journal article. IUD=intrauterine device.
*Single value for combined group provided when breakdown not available.
†Women aged ≤45 years received a progestin for contraception and other indications.
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RESEARCHTable 3| Total number of venous thromboembolic events and adjusted relative risk in women taking progestin-only contraceptives or no
hormone among included studies
Adjusted
relative risk of
Measure of
effect used
No of patients Mean (SD) age (years)
Study
No hormone Progestin
Controls (or
unexposed)
Cases (or
exposed)
VTE for users v
non-users(95%
CI) No VTE VTE No VTE VTE
1.20 (0.40 to
3.63)
Odds ratio 133 98 2 3 N/A N/A Barsoum et al,
2010
28
0.80 (0.2 to 3.9) Rate ratio* 96 6 99 3 29.7 (8.7) 29.6 (8.6) Conard et al,
2004
23
0.68 (0.28 to
1.66)
Odds ratio 1346 174 54 7 34.0 (7.4) 34.5 (6.6) Heinemann et al,
1999
20
0.77 (0.61 to
0.98)¶
Rate ratio§ N/A‡ 1812 N/A† 70 N/A N/A Lidegaard et al,
2011
24
1.30 (0.50 to
3.00)
Rate ratio** 102 20 27 7 N/A N/A Vaillant-Roussel
et al, 2011
22
1.30 (0.3 to 6.8) N/A 161 13 26 2 N/A N/A Vasilakis et al,
1999
25
1.38 (0.65 to
2.90)¶
Odds ratio 1102 421 41 23 39.5 (N/A) 39.9 (N/A) Van Hylckama
Vlieg et al, 2010
26
1.93 (0.97 to
3.84)¶
Odds ratio 2288 635 97 32 35.4 (6.8) 31.8 (7.1) for
oral, 31.0 (6.2)
for injectable
WHO, 1998
27
VTE=venous thromboembolic event. N/A=information not reported in original paper.
*Obtained from Poisson regression (incidence rate ratio) and Cox proportional hazards regression (hazard ratio); result from the Cox model shown
†Incidence rate/10000 woman years of VTE=2.0 to 3.5, depending on the type of progestin.
‡Incidence rate/10000 woman years of VTE=3.7 for non-users.
§Obtained from Poisson regression (incidence rate ratio).
¶Summary measure for all progestin-only contraceptive users versus non-users calculated based on the results from the different subgroups as reported in the
original paper.
**Hazard ratio obtained from Cox proportional hazards regression.
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RESEARCHFigures
Fig 1 Flow diagram of studies included in meta-analysis
Fig 2 Adjusted relative risk of venous thromboembolism for users versus non-users of a progestin-only contraceptive, all
subgroups combined
Fig 3 Unadjusted relative risk of venous thromboembolism for users versus non-users of a progestin-only contraceptive,
all subgroups combined
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RESEARCHFig 4 Adjusted relative risk of venous thromboembolism for users versus non-users of a progestin-only contraceptive,
injectable formulation only
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